Loading company
Autonomix Medical, Inc.
AMIX · Nasdaq · ·
Next earnings: November 11, 2026
$3.76-1.6%Sep 29 close
- 1M
- -20.7%
- 6M
- -55.5%
- 1Y
- -84.7%
AMIX · Nasdaq · ·
Next earnings: November 11, 2026
$3.76-1.6%Sep 29 close
Autonomix Medical, Inc. is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$2.7M | -$3.3M | +18.25% |
| Free Cash Flow | -$2.9M | -$8.3M | +65.00% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Autonomix Medical, Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Autonomix Medical, Inc.’s Item 2.02 8-K filed February 13, 2025; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.